-

binx health and WellStreet Urgent Care Increase Access to Chlamydia and Gonorrhea Testing and Care In-clinic

Program aims to dismantle barriers to STI care by offering convenient and cost-effective in-clinic testing solutions for patients seeking chlamydia and gonorrhea testing and treatment

BOSTON--(BUSINESS WIRE)--binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a new partnership with WellStreet Urgent Care, a leading healthcare provider based in Atlanta, Georgia. WellStreet Urgent Care is taking steps to improve the way patients access sexually transmitted infection (“STI”) treatment and care through advanced Point-of-Care (“POC”) technologies throughout WellStreet Urgent Care locations. The program is powered by the binx io, an FDA-cleared, CLIA-waived, molecular PCR chlamydia and gonorrhea ~30-minute test for male and female patients.

Together, WellStreet Urgent Care and binx health are redefining diagnostic access by providing patients and providers an avenue for same day test and treatment all in-clinic. With the launch of this program at 115 locations across WellStreet brands such as Piedmont, Corewell Health Urgent Care, Prisma Health and University Hospitals, WellStreet Urgent Care aims to reduce the barriers and challenges associated with traditional STI testing pathways. Today, patients are waiting on average 24-72 hours for a chlamydia and gonorrhea test result. This time lag can result in delayed or unnecessary treatment and further infection spread while increasing patient anxiety.1, 2

With the binx io, WellStreet Urgent Care will provide patients PCR reference lab-comparable results in the same patient visit, setting a new standard for patient care.

WellStreet’s Chief Operating and Medical Officer, Michael Duchynski, MD, MBA, said, “In urgent care, we often only get one opportunity to diagnose and treat our patients, and providing same-day testing, results, and treatment has a profound impact on patient outcomes. With the ability to test, receive results, and begin treatment all in one visit, we're not only improving patient satisfaction but also significantly enhancing the speed, quality, and effectiveness of care.”

STIs continue to pose a significant public health challenge, highlighting the need for new technologies geared at prevention and early detection. According to the Centers for Disease Control and Prevention (CDC) chlamydia and gonorrhea prevail as the two most common STIs with over 2 million cases in the U.S annually.3 These infections can be asymptomatic and if left untreated, can lead to long-term complications including infertility, chronic pelvic pain and increased susceptibility to other infections.4, 5 POC platforms like the binx io, make routine testing accessible and help to mitigate these negative health outcomes.

"Partnering with binx health to offer same-day molecular PCR testing and subsequent specific treatment for Chlamydia and Gonorrhea is critical,” said Brian S. Bobb, M.D., Senior Medical Officer, SVP at WellStreet Urgent Care. “By integrating this advanced testing technology into our clinics, we’re not only enhancing operational efficiency, but, more importantly, improving patient care by reducing wait time and anxiety. Diagnoses that used to take days to determine can now be confirmed via this seamless, one-visit approach, allowing us to provide timely, effective care while minimizing the risk of further transmission or complications. It’s a vital step toward delivering higher-quality, more accessible healthcare for our communities.”

Through a same day test and treat model, WellStreet Urgent Care and binx health are empowering individuals to take control of their sexual health in a way that is convenient, discreet, and affordable.

“Binx is incredibly proud to partner with WellStreet to bring POC male and female STI testing to their facilities throughout the US,” added binx Health President, Mike Karsonovich. “Urgent Cares play an integral role in how communities access healthcare and we at binx are very excited to play a part in helping WellStreet to improve patient access to such important sexual health diagnostics and care.”

Individuals within Georgia, Ohio and South Carolina can access same-day chlamydia and gonorrhea testing at participating WellStreet Urgent Care locations. Information on participating locations and prospective patient information can be found by visiting https://www.wellstreet.com/.

About WellStreet Urgent Care

Founded in 2011 in Atlanta, Georgia, WellStreet Urgent Care began as an independent operator and quickly expanded to a network of seven locations within its first year. In 2014, WellStreet pioneered its partnership model, joining forces with Piedmont Healthcare to extend the Piedmont Urgent Care brand across North Georgia. This model continued to evolve in 2019 when WellStreet partnered with Beaumont, now Corewell Health, to operate a network of urgent care centers in Southeastern Michigan. Further expanding its reach, WellStreet entered into new partnerships in early 2023 with University Hospitals and Prisma Health, strengthening its presence in the urgent care industry. Despite rapid growth, WellStreet remains dedicated to delivering best-in-class quality and an exceptional patient experience, ensuring uncompromising care for each patient, one at a time. WellStreet is committed to adapting and innovating to meet the healthcare needs of tomorrow, always prioritizing the well-being of those it serves.

About binx health

binx health is a leading healthcare technology and diagnostics company that aims to improve patient access to STI diagnostics at the Point of Care. The Company works with a variety of health care entities who have a significant interest in delivering or facilitating improved access to critical STI diagnostics in-clinic. Their most recent achievement, the binx io, is an FDA-cleared, CLIA-waived, molecular PCR chlamydia and gonorrhea test. Male and female patients can receive lab-comparable test result in ~30 minutes which enables providers to implement a same day test & treatment model for patients. For more information, please visit https://mybinxhealth.com/.

Citations
1.  

Huntington, S., Weston, G., & Adams, E. (2021). Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services. Therapeutic Advances in Infectious Disease, 8, 20499361211061645.

2.  

National Association of County and City Health Officials. (2021, December 9). STI testing: New point-of-care advances [PowerPoint slides]. NACCHO

3.  

Centers for Disease Control and Prevention. (2024, November 12). National overview of STIs in 2023. Centers for Disease Control and Prevention

4.  

Farley TA , Cohen DA , Elkins W . Asymptomatic sexually transmitted diseases: the case for screening. Prev Med 2003;36:502–9. doi:10.1016/S0091-7435(02)00058-0

5.  

https://www.hhs.gov/programs/topic-sites/sexually-transmitted-infections/index.html#:~:text=The%20current%20rise%20of%20STIs,certain%20cancers%2C%20and%20even%20infertility.

 

Contacts

Mike Geller
Profile Advisors
mgeller@profileadvisors.com

binx health


Release Versions

Contacts

Mike Geller
Profile Advisors
mgeller@profileadvisors.com

Back to Newsroom